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Introduction
It was believed that Type 2 diabetes (DM2) was a progressive 
condition, with gradual decrease in beta-cell function. Data from 
the United Kingdom Prospective Study indicate that approximately 
only 50% beta-cell function remains at the time of diagnosis 
which decreases to 30% within 6 years.1 This reduction in beta-
cell function is associated with treatment intensification including 
additional oral hypoglycaemic agents and ultimately insulin.1 Due to 
the decrease in beta-cell function, the first phase insulin response 
(insulin secretion within the first 10 minutes after eating) is believed 
to be permanently lost in people with Type 2 diabetes.2,3 Lim et al. 
(2011) challenged this view when the first phase insulin secretion 
normalised following a very low calorie diet (VLCD) (less than (<) 
600 kcal) for 8 weeks.4 Subsequently, glycaemic control normalised 
and DM2 was in remission. It is not surprising that this study led 
researchers to question if DM2 could be reversed3 and sparked mass 
interest in these diets from people living with DM2.5 
Weight Loss Approach
Traditionally medical nutritional therapy (MNT) for DM2 has focused 
on weight loss as an integral part of the overall management of 
DM2. Weight loss guidelines advocate for moderate calorie 
restriction of 500-1000 kcal from maintenance requirements to 
achieve approximately 0.45-0.9 kg weight loss per week.6 This 
widely practised guideline is not surprising, as a raised body 
mass index (BMI) is documented to be one of the primary causes 
of DM2.7 However, more recent evidence indicates that waist 
circumference is a greater predictor of obesity related conditions, 
including insulin resistance and DM2.8,9 The reason for this is that 
waist circumference is a surrogate marker of visceral or central 
adiposity.10 Visceral adiposity produces various adipokines involved 
in the development of DM2. Thus, the focus was to reduce BMI and 
waist circumference.
Despite the focus on weight loss, it is interesting to note that weight 
loss does not always improve glycaemic control.12 Furthermore, 
glycaemic control can improve without weight loss.13 Arguably, the 
most pronounced effects of weight loss on glycaemic control are 
seen following bariatric surgery. Early research showed that the 
rates of diabetes remission were nearly 90% 10 years after bariatric 
surgery.14 Research at the time associated diabetes remission 
with 15-20% weight loss.15 However, the effects of weight loss via 
conventional MNT appear to be less effective. Data from the LOOK 
AHEAD trial revealed that those participants who ≥ 15% weight 
loss only reduced fasting blood glucose levels by 1.6 mmol/l and 
haemoglobin A1c (HbA1C) by 0.9%, far from remission levels.16 
These findings posed the question: are there factors at work beyond 
weight loss? 
The Ectopic Approach 
With bariatric surgery there is rapid weight loss via VLCD 
(<800 kcal) pre and post-surgery.17 The use of VLCD prior to surgery 
reduces the overall size of the liver (through a decrease in hepatic 
fat content), thus making the procedure easier to perform.17,18 This 
is especially interesting in the light of recent evidence that suggests 
that ectopic fat in the liver and pancreas may be better predictors 
of DM2 than either waist circumference or BMI.3,19 The Fat Spillover 
Theory  (Figure 1) proposed that, due to genetic, ethnicity and age, 
fat ‘spills over’ from the subcutaneous tissue into the ectopic fat 
with the attendant metabolic abnormalities, including diabetes.19 
The understanding of ectopic fat and how it is reduced through 
VLCD explains why diabetes remission occurs within days after the 
surgery, before substantial weight loss has occurred.20 The approach 
to the management of DM2 then would seem to be to reduce 
ectopic fat.
Although, excess calories are the cause of obesity and ultimately 
ectopic fat in DM2, there are various other mechanisms that drive 
ectopic fat accumulation. The Twin Cycle (Figure 2) explains this 
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process in detail.3 During long term excess intake of calories, 
any excess carbohydrate intake undergoes de novo lipogenesis 
(conversion of excess carbohydrate to fatty acids), which promotes 
fat accumulation in the liver. De novo lipogenesis is stimulated by 
insulin, which is particularly relevant in patients with DM2 who 
present with initial hyperinsulinaemia due to insulin resistance. The 
increased de novo lipogenesis promotes further fat accumulation 
in the liver, which further increases insulin resistance and hepatic 
glucose production. Over time, this increases fasting blood glucose 
levels, which results in hyperinsulinaemia. The excess fat in the 
liver leads to an increase in very-low-density lipoprotein (VLDL) 
triglycerides, which increases fat delivery to all tissues, including 
the pancreatic islet cells. The excess fat in the islet cells impairs 
the acute insulin secretion in response to food, which results in 
postprandial hyperglycaemia and ultimately the onset of clinical 
diabetes. The Twin Cycle is switched off by severe calorie restriction, 
which may suggest that the reason moderate calorie restriction 
does not achieve diabetes remission is that the calorie content is 
too high to prevent hyperinsulinaemia and down-regulate de novo 
lipogenesis.
The Glucotoxic and Lipotoxic Approach 
Chronic hyperglycaemia temporarily suppresses insulin secretion and 
promotes insulin resistance. This has been termed glucotoxicity.21 
The clinical significance of such is clearly seen in patients treated 
with short-term insulin therapy at the time of diagnosis to correct the 
glucotoxicity. Results from the meta-analysis by Kramer, Kaercher 
and Retnakara concluded that patients treated with insulin for 2-3 
weeks at the time of diagnosis improved insulin secretion and 
reduced insulin resistance.22 After 2 years of such treatment, 42.1% 
of patients were in remission (off all oral hypoglycaemic agents). 
Excess calorie consumption and adiposity (especially ectopic fat) 
can result in chronic elevation of free fatty acid. The increase in free 
fatty acids temporarily suppresses insulin secretion and promotes 
insulin resistance. This has been termed lipotoxicity.21 The treatment 
of lipotoxicitiy is to reduce excess adiposity and improve glycaemic 
control, which in turn reduces free fatty acids.21
Therefore, the better approach would appear to be aggressive 
rapid resolution of both the gluco- and lipo-toxicity. As previously 
mentioned, insulin therapy is the most studied approach. The 
question therefore is: could MNT therapy be used as an effective 
alternative? Although there is no data to specifically address this 
question, we propose that conventional MNT will be ineffective. The 
reason being that the conventional MNT does not rapidly improve 
glycaemic control or reduce body weight but rather takes several 
months.23 However, VLCDs have been reported to rapidly improve 
glycaemic control and body weight within one week.4 VLCDs have 
shown to produce more rapid improvements in weight loss and 
glycaemic control compared to moderate calorie restriction at 3 
months.23 Therefore, if gluco- and lipo-toxicity were treated via MNT, 
it is reasonable to suggest that a VLCD would be the best approach.
Results on the use of very low calorie diets
The effects of VLCD are not new. In 1985, it was shown that 87% of 
the reduction in fasting blood glucose over 40 days on a VLCD (330 
kcal) occurred within the first 10 days in DM2, before substantial 
weight loss occurred.24 Fasting blood glucose rapidly reduced from 
16.5 to 8.8 mmol/l within 10 days. Thus, severe calorie restriction is 
a vital aspect of improving glycaemic control and VLCDs can rapidly 
improve fasting blood glucose levels. It is not surprising that calories 
influenced glycaemic control but what is interesting is the effect 
on the fasting blood glucose levels, which are largely determined 
by hepatic glucose output, insulin resistance and insulin secretion 
rather than dietary intake.3 
The safety of VLCD came under the spotlight around 1970.25 VLCDs 
became popular during this time due to the book The Last Chance 
Diet Book. There were 60 reported deaths from avid followers of 
this diet. The cause of death was due to ventricular arrhythmias. 
On closer evaluation it was noted that these diets were made 
up exclusively of poor quality protein with no micronutrient 
supplementation. The opinion at the time was that the deaths were 
due to electrolyte disturbances which would be a more likely cause 
of arrhythmias.25 Thus it was believed these people died due to 
protein and or micronutrient malnutrition. However, VLCDs currently 
contain high quality protein, carbohydrates, fat and micronutrients 
and have shown to be safe in a review by Henry.25 
A second possible explanation as to why such diets did not receive 
much interest could be due to the following common belief systems: 
“Small sustained changes in energy intake or expenditure will 
produce large, long-term weight changes” and ”Large, rapid weight 
loss is associated with poorer long-term weight-loss outcomes, 
as compared with slow, gradual weight loss”.26 These two belief 
systems have been deeply entrenched in obesity management but 
have been labelled  to be nothing more than a myth.26 Thus, small 
modest changes in weight do not produce large amounts of weight 
loss and rapid weight loss does not produce greater weight gain.26 
Despite the negative connotations surrounding VLCDs, the results 
from the study by Lim in 2011 got the world’s attention.4 In this 
study, 11 people with DM2 (DM duration = 2.5 years) were taken off 
all oral hypoglycaemic agents and placed on a VLCD (600 kcal) for 8 
weeks. Within 1 week, fasting blood glucose normalised and diabetes 
went into remission. Hepatic glucose production normalised, first 
phase insulin response returned and both hepatic and pancreatic 
fat reduced to levels similar in those without diabetes. Three months 
following the VLCD, there was a mean weight gain of 3.1 kg, however 
hepatic fat content did not increase and pancreatic fat continued to 
decrease. Despite the weight gain, 7 out of the 11 people were still 
in remission. 
The study by Lim left several questions unanswered, including 
whether this intervention will work in those who have had diabetes 
for a longer time. The answer to that question was provided by 
Steven and Taylor in 2015.27 They placed 29 people with DM2 on 
a VLCD (624-700 kcal). They were grouped according to duration 
98 2016;29(2)S Afr J Clin Nutr
SASPEN Case Discussion: The Use of Very Low Calorie Diets in the Management of Type 2 Diabetes Mellitus
of Diabetes with short duration of diabetes (mean = 2.3 years) and 
long term diabetes (mean = 12.7 years). All hypoglycaemic agents 
(including insulin) were stopped. After 8 weeks the mean fasting 
blood glucose had decreased from 9.6 to 5.8 mmol/l in the short 
duration group and from 13.4 to 8.4 mmol/l in the long duration 
group. Eighty seven percent of those in the short duration group 
and 50% of those in the long duration group were in remission after 
8 weeks. Further evaluation revealed that the fasting blood glucose 
was 5.8 mmol/l, 6.2 and 10.6 mmol/l at 8 weeks for those with 
diabetes for <4 years, 8-12 years and >12 years respectively. 
Thus, remission was less likely to occur in those with a longer 
diabetes duration. However, it should be noted that even though 
remission occurred in only 50% of those with long term diabetes, 
there was substantial improvement in glycaemic control despite no 
hypoglycaemic agents. 
A further question Lim left unanswered was what are the effects 
beyond 3 months? Steven and Taylor’s team published their work 
in March 2016 on the 6 month follow up of their previous study.28 
A weight maintenance diet was used to reintroduce solid food. One 
shake (Product C, Table 1) was exchanged for 1 solid meal every 
3 days. Once patients were entirely on the weight maintenance diet 
40% of the overall sample remained in remission. Interestingly, after 
6 months this increased to 43%. Weight increased by only 900 g after 
6 months of being on the VLCD. Remission at 6 months occurred in 
60% and 21% of the short and long duration groups respectively. 
Naturally, the final question is what about the long term 
consequences? Unfortunately there is limited data. The studies 
available often provided minimal follow up education beyond the 
VLCD phase. 
Wing et al. assessed the effects of a VLCD (400 kcal) vs. a low (1000-
1500 kcal) calorie diet in 36 individuals (16 VLCD, 17 low calorie) at 
1 year.29 HbA1c was 10.4% at baseline in both diets and decreased 
more so in the VLCD at 1 year (9.2 vs 11.8%). Fasting blood glucose 
also decreased more so in the VLCD (14.2 to 10.4 mmol/l vs. 
12.8 mmol/l to 14.5 mmol/l). The improvements in glycaemic control 
were despite similar weight loss at 1 year. Thus, suggesting an effect 
beyond weight loss. 
Snetl  et al. sought to determine the effects of a 16 week VLCD 
(450 kcal) in DM2 (DM duration = 9 years) patients treated with 
insulin (mean dose of 86 units) with or without oral agents.30 The 
study provided only basic dietary advice following the VLCD, with no 
follow up education. So possibly, due to the lack of education and 
follow up there was 13 kg weight gain, months after the completion 
of the VLCD. Despite the massive weight gain, body weight, hepatic, 
visceral, subcutaneous and pericardial fat were lower than they were 
at baseline. HbA1c decreased from 8.4% to 7% at 3 months during 
the VLCD and increased to 7.7% 18 months from baseline. Although 
the reduction of 0.7% from baseline was not statistically significant, 
we would argue that the results are clinically significant, especially 
since fewer patients were on insulin (100% on insulin vs. 28% 
on insulin at 18 months). The lesson learnt from this study is that 
16 weeks of a VLCD despite inadequate follow up produces long 
term benefits. 
Diabetes UK started a study to afford clarity on the use of VLCD 
(800 kcal) for people with DM2. This interest gave rise to The DIRECT 
(DIabetes REmission Clinical Trial) study which received funding 




Our first experience with VLCD (800 kcal) came from our work 
with Mr X. He lived with Type 2 diabetes for 5 years and weighed 
259 kg at the initial consultation. He was treated with 30 units 
of Actraphane BD and Metformin 1 g BD. His mean fasting blood 
glucose was 10 mmol/l and pre-dinner was 16 mmol/l. Over the 
course of 4 months through moderate (2100 kcal) calorie restriction 
his weight reduced to 209 kg. His mean fasting blood glucose was 
7 mmol/l and pre-dinner readings were 12 mmol/l. He was adamant 
that he wanted to stop using insulin. However, despite the 50 kg 
weight loss this seemed unlikely. He was placed on VLCD consisting 
of Product A (Table 1) 230 ml, three times a day (675 kcal) with 
non-starchy vegetables, such as leafy vegetables ad lib in attempt to 
discontinue insulin. Although Product C (Table 1) was used in most 
of the international studies, it is not available in South Africa and 
thus Product A was used instead (Table 1). The approach was to 
place him on the VLCD for 2 weeks, as by that stage 80% of the 
liver size and subsequently liver fat would have decreased based on 
the experience of a similar VLCD (456-680 kcal) study.32 His insulin 
was stopped the day before he started on the diet but the Metformin 
remained. 
Within the first week he had lost 8 kg, and his mean fasting blood 
glucose was 6.5 mmol/l and pre-dinner was 10 mmol/l despite 
no insulin. He reported that he was not hungry and agreed to 
continue into the second week. Due to logistical reasons, we were 
unfortunately not able to weigh him the following week. Despite this 
limitation, his mean fasting blood glucose levels were 5 mmol/l and 
pre-dinner 7 mmol/l. He was then placed on a moderate calorie diet 
(1700 kcal). Over the Christmas period he gained 3 kg, but as seen 
in the study by Lim there was no change in glycaemic control, with 
fasting readings of 5.5 mmol/l and pre-dinner 7 mmol/l. It has now 
been 5 months since the VLCD. He presently weighs 193 kg and 
his mean fasting blood glucose levels are 6 mmol/l and pre-dinner 
8 mmol/l, despite no insulin. 
Revised Approach
Since our initial experience, we have revised our approach and place 
our patients on VLCD (800 kcal) for 2 weeks consisting of only 3 
shakes of Product A and non-starchy vegetables ad lib (<800 kcal). 
This is then followed by two weeks of 2 shakes a day and one solid 
meal, usually a dinner of lean protein and vegetables, without a 
specific calorie restriction. Despite the latter, some patients prefer 
to continue on 3 shakes a day as they find it easier to adhere to. 
Following the VLCD, patients were requested to follow a moderate 
calorie diet with one shake per day. The use of a meal replacement 
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once a day following a VLCD produces 3.9 kg greater weight loss 
than dietary education alone.33 
Results
It is important to note that all the patients discussed under the 
“revised approach” section, going forward, have seen dietitians 
for a number of years with various dietary approaches being used. 
From our experience, none of these approaches have resulted in the 
level of enthusiasm and motivation that we have witnessed with the 
use of the VLCD. Furthermore, we have also not seen this level of 
success in such a short space of time. 
Our patient sample (Table 2) had diabetes for 9.9 years, were obese 
and had very poor glycaemic control and poor overall metabolic 
markers status. The reason for this was that the programme was 
offered to patients with suboptimal metabolic control. Anthropo-
metric measurements were taken at the start of the diet and 
glycaemic control was determined based on the self-monitoring of 
blood glucose levels in the preceding month. 
Patients each started the programme at various times, thus the 
overall length of being on the programme varied considerably (mean 
3.8 weeks). This influenced which stage of the programme the 
patient was on. Thus, this does limit the ability to assess the overall 
effectiveness of the programme. However, despite these limitations 
the data was compiled. 
The mean changes (Table 3) were in weight – 4.39 kg, in waist 
circumference – 4.32 cm and in BMI - 1.40 kg/m2 over the 
3.8 weeks duration of the study. Fasting blood glucose, pre-lunch 
and pre-dinner readings decreased by -3.07, -3.65 and -2.9 mmol/l, 
respectively (based on the mean of the readings over 3 days). 
The improvements in glycaemic control were noted despite a trend 
towards a reduction of hypoglycaemic agents including insulin 
(Table 3). Gliclazide was most often stopped as patients experienced 
hypoglycaemia. Patient 11 decided to stop all her treatment and was 
thus in “remission”. 
For those treated with insulin, the mean fasting, pre-lunch 
and pre-dinner readings at baseline were 10.75, 12.55 and 
10.30 mmol/l, respectively. The fasting, pre-lunch and pre-dinner 
readings decreased to 7.50, 7.30 and 6.98 mmol/l, respectively, 
over a mean of 4 weeks. Importantly, these improvements occurred 
despite having diabetes for 15 years, on average, and a reduction 
in insulin use. The total daily insulin dose was reduced from 121 to 
69 units, a 43% reduction. The effect of improved glycaemic control, 
despite large reductions in total daily insulin, was arguably most 
noticeable in patient 1, despite only being on the diet for 2 weeks. 
Most patients reported feeling satiated on Product A. A few patients 
changed to Product B for a number of reasons. Some patients 
experienced taste fatigue (n=3) as the product is only available in 
vanilla flavour. Some patients (n=5) experienced gastrointestinal side 
effects such as bloating, cramping and flatulence which may have 
been related to the polyols that are used to sweeten the product. 
Many patients have reported feeling better, and more energetic 
despite the lower calorie intake. This could be attributed to an 
improvement in overall blood glucose control. There were two 
patients with fibromyalgia who reported feeling less fatigued and 
having less pain.
Challenges
There have been requests for more free vegetable recipes as it 
became tiresome having the same vegetable dishes to fill up on in 
some instances. 
On initiation of the VLCD, it is important that medications be altered, 
especially the oral hypoglycaemic agents and insulin. We analysed 
home blood glucose readings closely and medical adjustments were 
given where necessary. For some patients few or even no reductions 
or increases in dosages were made.
Side effects that we observed in our patients were cold intolerance; 
the gastrointestinal symptoms that have been addressed above 
(n=5); hypoglycaemia (n=2) which can be corrected by decreasing 
the hypoglycaemic agents; as well as weakness which was reported 
by one man who was a power/weightlifter. Two patients reported that 
they were also constipated which could be improved by ensuring 
that adequate vegetable fibre was consumed.
Conclusion
The overall experience based on 11 patients, is that this is an 
effective approach to rapidly reduce blood glucose levels, reduce 
medication, and motivate patients. Based on the available literature 
we would deduce that this is the result from treating the cause of 
DM2 - ectopic fat- rather than its expression in the symptoms of 
metabolic derangements. 
The obvious limitation of our work is that this is not a randomised 
controlled trial, but rather a case series which limits the ability to 
ensure that this approach is superior to conventional nutritional 
therapy. The short duration – mean 3.82 weeks – provides only 
short-term outcomes, thus, we propose that further long-term 
studies be conducted. Our current sample will be monitored and thus 
reported on further in due course. 
The available guidelines surrounding the use of VLCDs are somewhat 
conflicting. The Canadian Diabetes Association does not suggest the 
routine use of very low calorie (<900 kcal) diets unless a patient is 
under medical supervision.34 The latest guidelines from the American 
Diabetes Association suggest that VLCDs (≤800 kcal) can be used for 
3 months provided that the treating clinician is adequately skilled 
and that the patient is monitored regularly.  The National Institute 
of Health and Clinical Excellence does not discuss VLCDs for Type 2 
diabetes, but a VLCD diet is mentioned in their obesity guidelines.35 
The guidelines suggest that VLCDs <1000 kcal can be used for a 
maximum of 3 months or 2-4 days a week, long term. However, 
VLCDs <600 kcal should only be used if clinical supervision is 
available. The Society of Endocrinology Metabolism and Diabetes of 
South Africa guidelines, which are due to released later this year, 
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mention that a VLCD (<800 kcal) diet can be used 
in Type 2 diabetes. 
Based on the available literature, patients 
recently diagnosed with Type 2 diabetes would 
appear to be more likely to go into remission.28 
However, the efficacy of the diet in patients who 
are on large doses of insulin is less clear. Despite 
the former, our results suggest that such an 
approach can drastically reduce total daily insulin 
use. Arguably, the most important question is 
who is likely to adhere to this diet? At present, 
we do not know, but patient 11 provided the 
following piece of information. “You do not have 
diabetes (name of clinician), therefore you do not 
understand what I am willing to do to improve my 
health. Do not make the judgement of whether 
I will or will not be able to follow this diet.” The 
lesson learnt is not to prejudge your patients but 
rather provide them with information regarding a 
VLCD as an alternative solution. 
Figure 1: Ectopic fat concept and the development of insulin resistance and DM2: The illustration 
shows the development and location of ectopic fat when the ability to store subcutaneous fat is 
exceeded.19
Figure 2: Twin cycle explains the aetiology of DM2 due to a positive calorie balance which leads to 
hepatic and pancreatic fat deposition.3 This fat deposition causes insulin resistance and hyper-insulin 
secretion, which ultimately results in DM2.
Table 1: Nutritional Content of the Supplements






Energy ( kcal / kJ) 225 / 947 230/ 967 207/870
Protein (g) 10.1 8.5 17.5
Fat (g) 8.2 7.5 4.5
Carbohydrate (g) 21.3 33.1 22.5
Fructooligosaccharides (g) 1.06 2.3 0
Polyols (g) 5.72 0 0
Fibre (g) 2.12 2.3 3.6
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Table 2: Baseline Data: Anthropometric measurements and biochemical values
Patient Age Duration 
of diabetes 
(years)











1 64 17.00 94.60 117.00 36.00 11.70 19.80 15.50 14.20
2 51 20.00 86.00 106.00 31.50 10.00 12.20 7.20 10.20
3 65 15.00 95.90 116.00 36.00 12.60 14.90 13.20 14.00
4 44 10.00 113.00 125.00 44.70 12.10 10.10 11.00 10.00
5 44 0.58 98.00 108.00 35.60 11.30 5.90 11.60 9.60
6 58 13.00 121.00 130.00 36.40 9.20 8.10 7.20 8.10
7 54 5.50 139.50 133.00 42.00 10.60 7.70 8.40 9.00
8 44 4.00 93.00 102.00 32.00 10.10 8.70 8.40 8.70
9 51 9.00 93.50 107.50 35.10 9.70 9.30 9.20 9.20
10 68 5.00 87.80 116.00 33.00 7.30 8.10 9.20 8.40
11 43 0.50 74.50 98.00 32.20 7.80 7.30 7.50 7.80
Average: 53.2727 9.90 99.71 114.41 35.86 10.22 10.19 9.85 9.93
Post Intervention Data: Anthropometric measurements and biochemical values 
Patient Age Duration 
of diabetes 
(years)














1*** 64 17.00 91.50 115.50 34.80 7.60 8.60 5.80 7.40 2.00
2* 51 20.00 83.00 107.00 30.40 8.00 7.30 10.00 9.00 5.00
3** 65 15.00 91.00 108.00 34.20 8.80 5.00 11.60 8.80 6.00
4*** 44 10.00 111.50 118.00 44.10 7.40 6.60 6.00 6.60 2.00
5*** 44 0.58 96.00 108.00 34.80 5.20 6.80 7.30 7.00 2.00
6** 58 13.00 109.00 125.00 33.60 7.30 6.70 6.10 6.60 5.00
7** 54 5.50 133.00 130.00 40.10 7.30 6.40 5.80 6.50 3.00
8** 44 4.00 85.50 95.00 29.50 8.70 7.60 6.30 7.90 5.00
9*** 51 9.00 90.90 106.50 34.10 7.10 6.80 6.40 6.70 1.00
10*** 68 5.00 86.00 108.00 32.70 4.90 5.10 5.40 5.90 3.00
11* 43 0.50 71.10 90.00 30.70 6.30 5.10 5.70 5.70 8.00
Average: 53.2727 9.90 95.32 110.09 34.45 7.15 6.55 6.95 7.10 3.82
Change: 4.39 4.32 1.41 3.07 3.65 2.91 2.83
Current stage of programme: *** = three shakes, ** = two shakes, *= one shake
Table 3: Baseline Data: Medication 






1 1000.00 105.00 100.00 205.00
2 2000.00 60.00 140.00 200.00
3 120.00 10.00 10.00
4 1700.00 30.00 28.00 58.00
5 120.00 50/500






Average 1600.00 96.00 50/500 66.75 61.00 121.00
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Post Intervention Data: Medication 









1*** 1000.00 30.00 70.00 100.00 2.00
2* 2000.00 30.00 120.00 150.00 5.00
3** 120.00 10.00 10.00 6.00
4*** 1700.00 24.00 20.00 44.00 2.00
5*** 50/500 2.00
6** 1700.00 20.00 21.00 41.00 5.00
7** 2000.00 60.00 3.00
8** 2000.00 1.80 5.00
9*** 1.00
10*** 2000.00 60.00 3.00
11* 8.00
Average 1771.43 80.00 50/500 1.80 26.00 48.20 69.00 3.82
Change -171.43 -240 † 0 -1.80 -40.75 -12.80 -52.00
Current stage of programme: *** = three shakes, ** = two shakes, *= one shake, † reduction from those who used Gliclazide at basline
